Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Review Article

Degradation of Androgen Receptor through Small Molecules for Prostate Cancer

Author(s): Raoling Ge, Xi Xu, Pengfei Xu, Lei Li, Zhiyu Li* and Jinlei Bian*

Volume 18 , Issue 7 , 2018

Page: [652 - 667] Pages: 16

DOI: 10.2174/1568009617666171107103936

Price: $65

Abstract

Prostate cancer is the most common carcinoma among aged males in western countries and more aggressive and lethal castration resistant prostate cancer often occurs after androgen deprivation therapy. The high expression of androgens and androgen receptor is closely related to prostate cancer. Efficient androgen receptor antagonists, such as enzalutamide and ARN-509, could be employed as potent anti-prostate cancer agents. Nevertheless, recent studies have revealed that F876L mutation in androgen receptor converts the action of enzalutamide and ARN-509 from an antagonist to agonist, so that novel strategies are urgent to address this resistance mechanism. In this review, we focus on the discussion about some novel strategies, which targets androgen receptor mainly through the degrading pathway as potential treatments for prostate cancer.

Keywords: Resistance mechanism, androgen receptor, degradation, prostate cancer, small molecules, new strategies.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy